PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133,036 | -16.5% | 12,829 | +15.3% | 0.00% | – |
| Q2 2023 | $159,368 | +37.8% | 11,129 | -31.3% | 0.00% | – |
| Q1 2023 | $115,661 | -4.9% | 16,199 | +49.4% | 0.00% | – |
| Q4 2022 | $121,658 | +3.1% | 10,843 | +1.4% | 0.00% | – |
| Q3 2022 | $118,000 | +37.2% | 10,691 | +5.3% | 0.00% | – |
| Q2 2022 | $86,000 | -45.2% | 10,149 | -12.1% | 0.00% | – |
| Q1 2022 | $157,000 | -37.9% | 11,541 | -10.1% | 0.00% | – |
| Q4 2021 | $253,000 | -35.5% | 12,839 | +5.3% | 0.00% | – |
| Q3 2021 | $392,000 | -7.8% | 12,197 | -3.0% | 0.00% | – |
| Q2 2021 | $425,000 | +52.3% | 12,569 | +69.3% | 0.00% | – |
| Q1 2021 | $279,000 | +4.1% | 7,425 | -8.1% | 0.00% | – |
| Q4 2020 | $268,000 | +21.8% | 8,082 | +34.5% | 0.00% | – |
| Q3 2020 | $220,000 | +21.5% | 6,011 | +9.5% | 0.00% | – |
| Q2 2020 | $181,000 | +88.5% | 5,491 | +48.0% | 0.00% | – |
| Q1 2020 | $96,000 | -20.7% | 3,710 | -5.5% | 0.00% | – |
| Q4 2019 | $121,000 | – | 3,926 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |